A set of ~800 largely isogenic deficiency stocks created by FLP-induced recombination between FRT-carrying transgenic insertions; molecularly defined deletion endpoints correspond to initial location of the progenitor insertions. Designed to fill gaps in deletion coverage and breakpoint placement; also used to replace older available deficiencies that have not been molecularly mapped.
CdsCB-0128-3/Df(3L)BSC795 as well as CdsEY08412/Df(3L)BSC795, CdsUM-8246-3/Df(3L)BSC795 and Cds1/Df(3L)BSC795 adult males are completely sterile.
The presence of P+PBac{XP5.RB3}BSC795 was verified using the PCR methods and primers described in FBrf0175003 with the substitution of the primer 5’-GCTTCTAAACGCTTACGCATAAACGATG-3’ for the RB3’ plus or RB3’ minus primer in the Hybrid PCR protocol in FBrf0174229.
The Gene Disruption project determined the insertion site of P{XP}d02504 to be Release 3 genomic coordinate 7828548 on arm 3L. This corresponds to Release 5 coordinate 3L:7862119 . The insertion site of PBac{RB}CG7375e02842 is Release 5 genomic coordinate 8190699 on arm 3L. Consequently, the breakpoints of Df(3L)BSC795 predicted from the Release 5 genomic coordinates of the progenitor P{XP}d02504 and PBac{RB}CG7375e02842 insertion sites are 3L:7862119 ;8190699 and the cytological breakpoints predicted from these coordinates are 66A17;66B12.